Business
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
Newly Published Data Shows Positive, Durable Benefits of the Only Minimally Invasive Treatment Approved for Patients with Homogeneous Emphysema, a Form of
About this update from Pulmonx Corporation
[{"type":"text","content":"\nNewly Published Data Shows Positive, Durable Benefits of the Only Minimally Invasive Treatment Approved for Patients with Homogeneous Emphysema, a Form of Severe COPD with Widespread Destruction of Lung Tissue\n\n REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nPulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long-term follow-up data of the IMPACT Study, a multi-center randomized clinical trial of the Zephyr® Valves. The IMPACT data show that Zephyr Valves deliver significant benefits to a group of severe COPD/emphysema patients that have very few treatment options because of widespread destruction of lung tissue across their lungs (also known as homogenous distribution of emphysema). The Zephyr Valve is the only endobronchial valve to receive approval from the FDA for treatment of patients with homogenous distribution of the disease, making it the only minimally invasive option to help these patients breathe easier once medications no longer control disease symptoms.\n\nThe findings reported in the July edition of RESPIRATION - International Journal of Thoracic Medicine1 show the durability of the benefits of Zephyr Valve treatment in patients with homogeneous emphysema out to at least 12-months with clinically and statistically significant improvements including:\n\n- Improved Lung Function (FEV1)\n- Sustained Increase in Quality of Life (SGRQ)\n- Increased Exercise Capacity (6MWD)\n- Long-term Reduction in Hyperinflation (RV) resulting in better breathing.\n\nThis is the first report of a multicenter study showing benefits out to at least one year for this patient population. The improvements from Baseline to 6-months seen in the Zephyr Valve group were maintained out to 12-months. Data for the medically managed control group was only available out to 6-months as these patients opted to have the Zephyr Valve procedure after completing the 6-month evaluation.\n\n“This is very important data because patients with severe COPD/emphysema have few treatment options once medications no longer alleviate symptoms. Those with homogenous emphysema, where the disease is equally spread throughout the lungs, have had even fewer options,” states Ralf Eberhardt, MD, Professor of Medicine of the Thoraxklinik at the University of Heidelberg, ...